What is the Need for Prostatic Biomarkers in Prostate Cancer Management?

Martin Spahn, Silvan Boxler, Steven Joniau, Marco Moschini, Bertrand Tombal, R. Jeffrey Karnes

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.

Original languageEnglish (US)
Article number70
JournalCurrent urology reports
Issue number10
StatePublished - Oct 18 2015


  • Biomarkers
  • Genetics
  • Microenvironment
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'What is the Need for Prostatic Biomarkers in Prostate Cancer Management?'. Together they form a unique fingerprint.

Cite this